RESOURCES
On the fence about mushrooms? Would you like to learn more about psilocybin from reputable sources? We’ve compiled a list of studies, articles and news to help you make an informed decision. Please read the articles and share this page with your loved ones. These articles were not written by us and are unbiased.
In a small study of adults with major depression, Johns Hopkins Medicine researchers report that two doses of the psychedelic substance psilocybin, given with supportive psychotherapy, produced rapid and large reductions in depressive symptoms, with most participants showing improvement and half of study participants achieving remission through the four-week follow-up.
November 4th 2020
Certain mental health disease states and symptoms have been studied, including depressed mood, anxiety disorders, obsessive-compulsive disorder, alcohol use disorder, and tobacco use disorder. This article provides an in-depth review of the study design and results of psilocybin in each of these conditions and discusses the clinical potential for use.
Magic mushrooms are undergoing a transformation from illicit recreational drug to promising mental health treatment. Numerous studies have reported positive findings using psilocybin—the mushrooms’ main psychoactive compound—for treating depression as well as smoking and alcohol addiction, and for reducing anxiety in the terminally ill. Ongoing and planned studies are testing the drug for conditions that include opioid dependence, PTSD and anorexia nervosa.
August 1, 2022
Magic mushrooms are undergoing a transformation from illicit recreational drug to promising mental health treatment. Numerous studies have reported positive findings using psilocybin—the mushrooms’ main psychoactive compound—for treating depression as well as smoking and alcohol addiction, and for reducing anxiety in the terminally ill. Ongoing and planned studies are testing the drug for conditions that include opioid dependence, PTSD and anorexia nervosa.
January 27th, 2021
Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression.
November 4th, 2020
April 8th, 2022
When administered under psychologically supportive, double-blind conditions, a single dose of psilocybin produced substantial and enduring decreases in depressed mood and anxiety along with increases in quality of life and decreases in death anxiety in patients with a life-threatening cancer diagnosis. Ratings by patients themselves, clinicians, and community observers suggested these effects endured at least 6 months.
April 11, 2022
November 30, 2016
We found psilocybin microdosing to be associated with improvements in mood and mental health, which adds to the growing body of research that suggests positive benefits of microdosing specifically in the domains of mental health and cognition.
— Joseph Rootman, study co-author
July 25, 2022
Psychedelics treatment can really affect people in many, many layers. One of them would be to affect our consciousness and allow us to look differently at the problem that we experienced before that.I just spoke with a very well-known psychiatrist. There’s something in psychiatry that cause “elephant path”, meaning that elephants will always go in the same path, they will never change the path. We are very similar, in that when we have this memory or thinking of something that traumatize us- it causes PTSD, depression, alcoholism.
Oct 21, 2022
Memory impairment, injury accidents, liver disease, and death: These are potential outcomes for patients with alcohol use disorder (AUD), according to NYU Langone Health. But hope may be in sight. Psilocybin-assisted psychotherapy may reduce patients’ number of heavy drinking days, paving the way for treatment that merges traditional therapy with psychedelics.
October 18, 2022
Now, medical researchers are exploring ways to harness magic mushrooms and other psychedelic substances to help treat mental health conditions like depression, addiction, and PTSD—sometimes with dramatic results. But what actually happens in the brain during a psychedelic experience? Fred Barrett, a neuroscientist at Johns Hopkins University, is one of the scientists trying to figure that out. His work suggests that “a brain region called the claustrum may be at the center of all of this,” he told NOVA.
October 19, 2022
Psilocybin, better known as the stuff that makes mushrooms magic, is the next big wellness industry—and a new frontier for mental health. If you hadn’t noticed psilocybin’s move toward the mainstream, a company like Numinus will come as a surprise. Led by founder and CEO Payton Nyquvest, Numinus is a brand-fantasy of the next iteration of wellness: clean, straightforward, empathetic, inclusive and self-aware. It’s one of several Canadian companies—Field Trip Health and Wellness among them—ready to capitalize on psilocybin. Its head office in Vancouver’s Gastown may look like any random vegan café, but instead of cookies, it has ketamine—currently the main psychedelic legally used in therapy in Canada.
January 20, 2023
Patients in Alberta will now be able to legally consider adding psychedelic-assisted therapy to the list of treatment options available for mental illnesses. Alberta psychiatrists and policymakers suggest that they are getting ahead of the curve by creating regulations to ensure the safe use of these hallucinogenic substances in a therapeutically supported environment. As of Jan. 16, the option is available only through registered and licensed psychiatrists in the province. Alberta’s new policy may set a precedent that moves Canadians one step closer to accepting psychedelics as medicinal substances, but historically these drugs were widely sought out for recreational and non-clinical purposes. And, if cannabis has taught us anything, medicalizing may simply be a short stop before decriminalizing and commercializing.
January 15, 2023
A new study published in the Journal of Psychopharmacology is the first to characterize the psychological impacts of psilocybin among people with bipolar disorder. The findings indicate that many people with bipolar disorder who consume psilocybin, the primary psychoactive component of psychedelic “magic mushrooms,” believe that the experience is helpful. However, many also report adverse outcomes, such as manic symptoms. Psilocybin-assisted therapy for depression is gaining attention due to promising research results over the past decade. A growing body of evidence suggests that, when combined with supportive therapy, ingesting certain psychedelic compounds in a controlled setting can lead to better mental health outcomes for individuals suffering from various mental disorders. However, it is unclear whether psilocybin holds any promise for those with bipolar disorder.
January 21, 2023
